Reference

Susceptibility of Neisseria gonorrhoeae to ceftizoxime in vitro and in vivo

Susceptibility of Neisseria gonorrhoeae to ceftizoxime in vitro and in vivo. Korting, H. C.; Neubert, U. (Dermatol. Klin. Poliklin., Ludwig-Maximilian-Univ., Munich, Fed. Rep. Ger.). Chemotherapy (Basel), 30(5), 322-7 (English) 1984. CODEN: CHTHBK. ISSN: 0009-3157. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 10 Ceftizoxime (I) [68401-81-0], a new b-lactamase-resistant cephalosporin, was tested for its potential efficacy in the cure of uncomplicated gonorrhea. While more than 50% of the 102 freshly isolated N. gonorrhoeae strains examd. were partially or totally resistant to penicillin [min. inhibitory concn. (MIC) 3 0.06 mg/mL], most of these strains proved highly susceptible to ceftizoxime (as well as cefotaxime). The MIC90% amounted to 0.004 mg/mL, while serum levels after the i.m. application of as little as 0.5 g exceed 1 mg/mL for more than 6 h. A single i.m. application of 1 g of ceftizoxime was effective in patients suffering from uncomplicated gonorrhea. Anaphylactic shock or rashes were not obsd. Thus, the i.m. application of 1 g of ceftizoxime is a reliable and safe treatment for uncomplicated gonococcal urethritis and cervicitis.

Third-generation cephalosporins: a critical evaluation

Third-generation cephalosporins: a critical evaluation. Barriere, Steven L.; Flaherty, John F. (Coll. Pharm., Univ. Michigan, Ann Arbor, MI, USA). Clin. Pharm., 3(4), 351-73 (English) 1984. CODEN: CPHADV. ISSN: 0278-2677. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) Section cross-reference(s): 10 A review with 313 refs. of the pharmacol. of 6 third-generation cephalosporins: cefotaxime [63527-52-6], moxalactam [64952-97-2], cefoperazone [62893-19-0], ceftizoxime [68401-81-0], ceftriaxone [73384-59-5], and cefmenoxime [65085-01-0].